Exelixis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,147

Employees1,147

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,147

Employees1,147

EXEL Key Statistics

Market cap

10.57B

Market cap10.57B

Price-Earnings ratio

18.82

Price-Earnings ratio18.82

Dividend yield

—

Dividend yield—

Average volume

2.31M

Average volume2.31M

High today

$39.60

High today$39.60

Low today

$38.62

Low today$38.62

Open price

$39.33

Open price$39.33

Volume

2.18M

Volume2.18M

52 Week high

$49.62

52 Week high$49.62

52 Week low

$27.86

52 Week low$27.86

EXEL News

Nasdaq 1d

First Week of December 19th Options Trading For Exelixis

Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the December 19th expiration. At Stock Options Channel , our YieldBoost...

TipRanks 4d

Exelixis: Buy Rating Backed by Strategic Positioning and Growth Prospects

Exelixis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ashwani Verma from UBS maintained a Buy rating on the stock and h...

Simply Wall St 5d

How Positive STELLAR-303 Results and Pipeline Advances Will Impact Exelixis Investors

Exelixis recently reported positive topline results from the STELLAR-303 phase 3 trial of zanzalintinib in metastatic colorectal cancer and launched a pivotal t...

Analyst ratings

57%

of 21 ratings

Buy

57.1%

Hold

42.9%

Sell

More EXEL News

The Motley Fool 5d

The Ultimate Biotech Stock to Buy With $50 Right Now

This innovative drugmaker still has plenty of upside potential. Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't eas...

TipRanks 5d

Exelixis Hold Rating: Modest Sales Forecasts and Competitive Challenges Amid Upcoming STELLAR-303 Data

In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Hold rating on Exelixis, with a price target of $45.00. Elevate Your...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

VeriSign

United Therapeutics

Sprouts Farmers Market

Gilead Sciences

Franco-Nevada

Kinross Gold